We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
Read MoreHide Full Article
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Bayer Aktiengesellschaft (BAYRY - Free Report) and Roche Holding AG (RHHBY - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Right now, Bayer Aktiengesellschaft is sporting a Zacks Rank of #2 (Buy), while Roche Holding AG has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that BAYRY likely has seen a stronger improvement to its earnings outlook than RHHBY has recently. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
BAYRY currently has a forward P/E ratio of 8.27, while RHHBY has a forward P/E of 15.62. We also note that BAYRY has a PEG ratio of 3.31. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. RHHBY currently has a PEG ratio of 4.23.
Another notable valuation metric for BAYRY is its P/B ratio of 1.37. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, RHHBY has a P/B of 7.17.
Based on these metrics and many more, BAYRY holds a Value grade of A, while RHHBY has a Value grade of C.
BAYRY is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that BAYRY is likely the superior value option right now.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Bayer Aktiengesellschaft (BAYRY - Free Report) and Roche Holding AG (RHHBY - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Right now, Bayer Aktiengesellschaft is sporting a Zacks Rank of #2 (Buy), while Roche Holding AG has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that BAYRY likely has seen a stronger improvement to its earnings outlook than RHHBY has recently. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
BAYRY currently has a forward P/E ratio of 8.27, while RHHBY has a forward P/E of 15.62. We also note that BAYRY has a PEG ratio of 3.31. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. RHHBY currently has a PEG ratio of 4.23.
Another notable valuation metric for BAYRY is its P/B ratio of 1.37. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, RHHBY has a P/B of 7.17.
Based on these metrics and many more, BAYRY holds a Value grade of A, while RHHBY has a Value grade of C.
BAYRY is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that BAYRY is likely the superior value option right now.